The Experts below are selected from a list of 22584 Experts worldwide ranked by ideXlab platform
Beate Schmoelethoma - One of the best experts on this subject based on the ideXlab platform.
-
sequential administration of 13 valent Pneumococcal conjugate Vaccine and 23 valent Pneumococcal polysaccharide Vaccine in Pneumococcal Vaccine naive adults 60 64 years of age
Vaccine, 2014Co-Authors: Richard N Greenberg, Alejandra Gurtman, Robert W Frenck, Cynthia Strout, Kathrin U Jansen, James Trammel, Daniel A Scott, Emilio A Emini, William C Gruber, Beate SchmoelethomaAbstract:Abstract Background Unlike free Pneumococcal polysaccharide Vaccines (PPSVs), Pneumococcal conjugate Vaccines (PCVs) induce a T–cell–dependent immune response. The study assessed potential influence of initial 13-valent PCV (PCV13) or 23-valent PPSV (PPSV23) on subsequent Vaccine administrations. Methods We conducted a randomized, modified double-blind study in 720 Pneumococcal Vaccine–naive adults 60–64 years of age. Subjects received either PCV13 at year 0 and PCV13 at year 1; PCV13 at year 0 and PPSV23 at year 1; or PPSV23 at year 0 and PCV13 at year 1. AntiPneumococcal opsonophagocytic activity (OPA) titers were measured before and 1 month after each vaccination. Results OPA titers following PPSV23 given 1 year after PCV13 (PCV13/PPSV23) (a) were noninferior for the 12 common serotypes and significantly higher for 6 of 12 common serotypes than those following only an initial PPSV23; and (b) were significantly higher for 11 of 12 common serotypes compared with PPSV23 followed by PCV13 (PPSV23/PCV13). In addition, PPSV23 followed 1 year later by PCV13 (PPSV23/PCV13) elicited significantly lower OPA titers than after only an initial dose of PCV13 for all 13 serotypes. Responses after a second vaccination with either PCV13 (PCV13/PCV13) or PPSV23 (PCV13/PPSV23) were noninferior for 9 of 13 and 8 of 12 common serotypes compared with the initial PCV13 dose. Conclusion In Pneumococcal Vaccine–naive adults 60–64 years of age, an initial PCV13 augmented the antiPneumococcal response to subsequent administration of PPSV23 for many of the serotypes in common to both Vaccines. In contrast, an initial PPSV23 resulted in a diminished response to subsequent administration of PCV13 for all serotypes. With a relatively short 1-year interval between doses, responses after a second vaccination with PCV13 (PCV13/PCV13) or PPSV23 (PCV13/PPSV23) were noninferior for a majority of serotypes compared with the initial PCV13 dose, probably reflecting the need for a longer interval between Vaccine administrations. ClinicalTrials.gov Identifier: NCT00574548 .
-
immunogenicity and safety of a 13 valent Pneumococcal conjugate Vaccine compared to a 23 valent Pneumococcal polysaccharide Vaccine in Pneumococcal Vaccine naive adults
Vaccine, 2013Co-Authors: Lisa A Jackson, Alejandra Gurtman, Kathrin U Jansen, Daniel A Scott, Emilio A Emini, William C Gruber, Martin Van Cleeff, Deepthi Jayawardene, Carmel Devlin, Beate SchmoelethomaAbstract:Background Streptococcus pneumoniae is a major cause of morbidity and mortality among adults 50 years of age and older in the United States. Pneumococcal conjugate Vaccines are efficacious against Pneumococcal disease in children and may also offer advantages in adults. Methods We performed a randomized, modified double-blind trial that compared a single dose of 13-valent Pneumococcal conjugate Vaccine (PCV13) with 23-valent Pneumococcal polysaccharide Vaccine (PPSV23) in 831 Pneumococcal Vaccine naive adults 60-64 years of age. An additional group of 403 adults 50-59 years of age received open-label PCV13. Anti-Pneumococcal opsonophagocytic activity (OPA) titers were measured at baseline, and at 1 month and 1 year after vaccination. Results In the randomized trial, the month 1 post-vaccination OPA geometric mean titers in the PCV13 group were statistically significantly higher than in the PPSV23 group for 8 of the 12 serotypes common to both Vaccines and for serotype 6A, a serotype unique to PCV13, and were comparable for the other 4 common serotypes. The immune response to PCV13 was generally greater in adults 50-59 years of age compared to adults 60-64 years of age. OPA titers declined from 1 month to 1 year after PCV13 administration but remained higher than pre-vaccination baseline titers. Conclusions PCV13 induces a greater functional immune response than PPSV23 for the majority of serotypes covered by PCV13, suggesting that PCV13 could offer immunological advantages over PPSV23 for prevention of Vaccine-type Pneumococcal infection.
Daniel M Musher - One of the best experts on this subject based on the ideXlab platform.
-
initial and subsequent response to Pneumococcal polysaccharide and protein conjugate Vaccines administered sequentially to adults who have recovered from Pneumococcal pneumonia
The Journal of Infectious Diseases, 2008Co-Authors: Moon H Nahm, Daniel M Musher, Adriana M Rueda, Edward A Graviss, Maria C RodriguezbarradasAbstract:Background Controversy persists over the benefits of Pneumococcal polysaccharide Vaccine (PPV) in at-risk adults. We studied PPV, protein-conjugate Pneumococcal Vaccine (PCV), or immunologic ‘priming’ with PCV followed by ‘boosting’ with PPV in adults who recovered from Pneumococcal pneumonia.
-
igg antibody to Pneumococcal capsular polysaccharide in human immunodeficiency virus infected subjects persistence of antibody in responders revaccination in nonresponders and relationship of immunoglobulin allotype to response
The Journal of Infectious Diseases, 1996Co-Authors: Maria C Rodriguezbarradas, Janardan P. Pandey, Jean E Groover, Christine E Lacke, Dieter W Gump, Christopher J Lahart, Daniel M MusherAbstract:Human immunodeficiency virus (HIV)-infected persons are less likely than are noninfected persons to respond to vaccination with Pneumococcal polysaccharides (PPS). Among those who respond, however, similar IgG levels may be achieved. HIV-infected men immunized with Pneumococcal Vaccine were classified as high- or low-level responders (IgG ≥1 μg/mL for ≥3 of 5 PPS [high] or for ≤1 PPS [low]). One and 2 years after immunization, geometric mean IgG levels and the percentages of subjects with IgG levels ≥1 μg/mL were similar for HIV-infected and for healthy high-level responders (controls) for all PPS except for serotype 8. Among HIV-infected low-level responders, revaccination with a double dose of Pneumococcal Vaccine did not stimulate IgG responses. Responsiveness of HIV-infected white patients was significantly associated with the Km(1)-negative allotype. These findings support current general recommended guidelines for administering Pneumococcal Vaccine to HIV-infected persons. Nonresponders will not benefit from revaccination.
Kenji Kawakami - One of the best experts on this subject based on the ideXlab platform.
-
a japanese nationwide survey of 23 valent Pneumococcal capsular polysaccharide Vaccine ppsv23 coverage among patients with chronic medical condition aged 50 and older
Human Vaccines & Immunotherapeutics, 2020Co-Authors: Kenji Kawakami, Atsushi Nakamura, Akira Wakana, Temitope Folaranmi, Tomoharu IinoAbstract:ABSTRACTThe 23-valent capsular polysaccharide Pneumococcal Vaccine (PPSV23) was introduced in Japan’s routine immunization schedule October 2014. It was recommended for adults aged 65 years (includ...
-
additive effect of Pneumococcal Vaccine and influenza Vaccine on acute exacerbation in patients with chronic lung disease
Vaccine, 2008Co-Authors: Akitsugu Furumoto, Yasushi Ohkusa, Meng Chen, Kenji Kawakami, Hironori Masaki, Yoshiko Sueyasu, Tomoaki Iwanaga, Hisamichi Aizawa, Tsuyoshi Nagatake, Kazunori OishiAbstract:To determine the clinical efficacy of combined vaccination with 23-valent Pneumococcal Vaccine (PV) and influenza Vaccine (IV) against pneumonia and acute exacerbation of chronic lung diseases (CLD), we conducted an open-label, randomized, controlled study among 167 adults with CLD over a 2-year period. Subjects were randomly assigned to a PV + IV group (n = 87) or an IV group (n = 80). The number of patients with CLD experiencing infectious acute exacerbation (P = 0.022), but not pneumonia (P = 0.284), was significantly lower in the PV + IV group compared with the IV group. When these subjects were divided into subgroups, an additive effect of PV with IV in preventing infectious acute exacerbation was significant only in patients with chronic obstructive pulmonary diseases (P = 0.037). In patients with CLD, the Kaplan–Meier survival curves demonstrated a significant difference for infectious acute exacerbation (P = 0.016) between the two groups. An additive effect of PV with IV on infectious acute exacerbation was found during the first year after vaccination (P = 0.019), but not during the second year (P = 0.342), and was associated with serotype-specific immune response in sera of these patients who used PV during the same period.
Cruz M Fuentes - One of the best experts on this subject based on the ideXlab platform.
-
effectiveness of the 23 valent polysaccharide Pneumococcal Vaccine against invasive Pneumococcal disease in people 60 years or older
BMC Infectious Diseases, 2010Co-Authors: Angel Vilacorcoles, Olga Ochoagondar, Jorge A Guzman, Teresa Rodriguezblanco, Elisabet Salsench, Cruz M FuentesAbstract:Background The 23-valent polysaccharide Pneumococcal Vaccine (PPV) is currently recommended in elderly and high-risk adults. However, its efficacy in preventing Pneumococcal infections remains controversial. This study assessed the clinical effectiveness of vaccination against invasive Pneumococcal disease (IPD) among people over 60 years.
Edward N Janoff - One of the best experts on this subject based on the ideXlab platform.
-
humoral responses to oxidized low density lipoprotein and related bacterial antigens after Pneumococcal Vaccine
Translational Research, 2007Co-Authors: John T Nguyen, Nicollette Myers, Jana Palaia, Angeliki Georgopoulos, Jeffrey B Rubins, Edward N JanoffAbstract:Antibodies to oxidized low-density lipoprotein (oxLDL) may modulate the development of atherosclerosis. Antibodies to oxLDL may also react with cell wall polysaccharides (CWPS) of Streptococcus pneumoniae because both antigens share a common phosphorylcholine moiety. In hypercholesteremic mice, immunization with Pneumococcal organisms elicited antibodies to oxLDL and protection against atherosclerosis. In humans, we determined whether the widely used adult Pneumococcal polysaccharide Vaccine augmented antibodies to oxLDL, CWPS, and phosphorylcholine, providing the potential to retard atherogenesis. Before and 4 weeks after Pneumococcal vaccination of 23 healthy adults (11 smokers and 12 matched nonsmokers), we characterized IgG, IgM, and IgA to Pneumococcal capsular polysaccharides, CWPS, and phosphorylcholine, IgG and IgM to oxLDL, and fasting serum lipids. The Pneumococcal Vaccine elicited significant increases in each antibody class to surface capsular polysaccharides. In contrast, only IgG to CWPS increased modestly and only among smokers. Moreover, antibodies to neither phosphorylcholine nor oxLDL increased consistently in either group. The Pneumococcal polysaccharide Vaccine effectively elicits antibodies to the bacterial capsule. The Vaccine had no effect on serum lipids. The Vaccine did not augment antibodies to CWPS, to its component phosphorylcholine, or to oxLDL, which are antibodies that have been proposed to modify the uptake of oxLDL by macrophages and the pathogenesis of atherosclerosis.
